市場消息：卡塔爾方面表示，華盛頓與德黑蘭之間的核問題等議題正在審議中。

Ant Group completed a board reshuffle, appointing three new independent directors: Bai Chong'en, dean of Tsinghua University School of Economics and Management; He Xiaopeng, chairman and CEO of XPeng Motors; and Zeng Shunfu, former CEO of Deloitte China. Former HKEX chair Shi Meilun and AI scholar Zhang Hongjiang remain on the board. The board stays at nine members, with independent directors exceeding 50%, a move the group says strengthens governance.

The National Medical Products Administration, via its priority review channel, has granted conditional approval to Chengdu Bailiduote Biopharma Co., Ltd.'s injectable monoclonal antibody Lunkangyilongtuo (trade name Yizekang). Indication: adults with recurrent or metastatic nasopharyngeal carcinoma who progressed after at least two lines of systemic chemotherapy and prior PD‑1/PD‑L1 inhibitor therapy. The approval adds a new treatment option for this patient cohort.